Soliris

The Profitable Business of Developing Orphan Drugs

The Profitable Business of Developing Orphan Drugs

Motley Fool

New Clinical Trial Data Show Substantial Improvement with Eculizumab (Soliris®) in Patients with STEC-HUS

New Clinical Trial Data Show Substantial Improvement with Eculizumab (Soliris®) in Patients with STEC-HUS

Business Wire

How A $440,000 Drug Is Turning Alexion Into Biotech's New Innovation Powerhouse

How A $440,000 Drug Is Turning Alexion Into Biotech's New Innovation Powerhouse

Forbes

Rare diseases mean big profits for Alexion

Rare diseases mean big profits for Alexion

CNN/Fortune

Alexion's Soliris to Merck's Januvia, top 20 generate huge growth

Alexion's Soliris to Merck's Januvia, top 20 generate huge growth

Fierce Pharma

Alexion Smashes Street's Estimates As Soliris Shines

Alexion Smashes Street's Estimates As Soliris Shines

Investors.com

The Cure for Alexion

The Cure for Alexion

TheStreet.com

Alexion Pharmaceuticals: A Tricky Mix Of Biotech And Pharma

Alexion Pharmaceuticals: A Tricky Mix Of Biotech And Pharma

Seeking Alpha

Alexion 3Q profit rises on growing Soliris sales

Alexion 3Q profit rises on growing Soliris sales

Yahoo/AP

Alexion, Celgene Resilient Vs. Volatile Market

Alexion, Celgene Resilient Vs. Volatile Market

Investors.com